论文部分内容阅读
目的:探讨PF新辅助化疗方案在进展期胃癌中的应用效果。方法:将我院70例进展期胃癌患者按照化疗方案的不同分为观察组和对照组,两组均采用新辅助化疗,对照组采用FOLFOX方案治疗,观察组采用PF方案治疗,比较两组患者的近期疗效及毒副反应。结果:观察组的近期总有效率为57.1%,与对照组的54.4%相比,无统计学意义(P>0.05)。但观察组的毒副反应显著少于对照组(P>0.05)。结论:FOLFOX与PF新辅助化疗方案治疗进展期胃癌疗效相当,但采用PF方案患者的耐受性更好。
Objective: To investigate the effect of PF neoadjuvant chemotherapy regimen in advanced gastric cancer. Methods: Seventy patients with advanced gastric cancer in our hospital were divided into observation group and control group according to the different chemotherapy regimen. Both groups were treated with neoadjuvant chemotherapy. The control group was treated with FOLFOX regimen. The observation group was treated with PF regimen. The recent efficacy and side effects. Results: The total effective rate in the observation group was 57.1%, which was not significantly different from that in the control group (54.4%) (P> 0.05). However, the adverse reactions in the observation group were significantly less than those in the control group (P> 0.05). Conclusions: FOLFOX is equivalent to PF neoadjuvant chemotherapy in the treatment of advanced gastric cancer, but PF patients have better tolerability.